A Registry of AL Amyloidosis (ReAL)

Launched by FONDAZIONE IRCCS POLICLINICO SAN MATTEO DI PAVIA · Apr 7, 2021

Keywords

ClinConnect Summary

The ReAL trial is a study aimed at creating a large registry of patients diagnosed with AL amyloidosis, a condition where abnormal proteins build up in the body and can cause various health problems. This registry will help researchers gather important information about the disease and how it affects patients. The trial is currently looking for participants aged 18 and older who have been diagnosed with systemic AL amyloidosis and have not yet received treatment. It's important that participants are willing to provide their medical information and continue follow-up care at the participating center.

If you or someone you know is considering joining this trial, participants can expect to share their health information and undergo regular check-ups at the study center. This research is critical as it will help improve understanding of AL amyloidosis and potentially lead to better treatment options in the future. Please note that individuals with other types of amyloidosis or those who have previously received treatment for AL amyloidosis are not eligible to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. diagnosis of systemic AL amyloidosis;
• • 2. treatment-naïve (pre-treatment data collected at participating center available for retrospective part);
• • 3. age ≥18 years;
• • 4. ability to understand and willingness to sign an informed consent (patients who already sign informed consent for clinical data to be used in retrospective analyses will be accepted);
• • 5. planned (or ongoing) follow-up at participating center.
• Exclusion Criteria:
• • 1. non-AL amyloidosis;
• • 2. previous treatment for AL amyloidosis.